Thermo Fisher's acquisition of Qiagen fails

Thursday, 13. August 2020 13:48

Thermo Fisher Scientific announced on Thursday that its offer to buy Qiagen N.V. lapsed after the minimum acceptance threshold for the number of offered shares was not satisfied by August 10. Settlement agents said 107,546,187 Qiagen shares were offered, or 47.02% of the company by acceptance deadline. As a result, Qiagen, a molecular diagnostics and sample preparation technologies company, will have to pay Thermo Fisher $95 million.

"Thermo Fisher is a disciplined acquirer with a strong track record of executing value-creating transactions. We remain extremely well-positioned to deliver on our proven growth strategy and continue to generate significant returns for our shareholders," Thermo Fisher CEO Marc Casper said.

Earlier, Thermo Fisher agreed to buy Qiagen for €9 billion.

Related Links: QIAGEN N.V.Thermo Fisher Scientific Inc.
Breaking the News / VP